Serum biomarkers for detection of head and neck squamous cell carcinoma.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 24995714.
- Also identified by DOI 10.1002/hed.23842 and PMC identifier 4317379.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Detection of hypermethylated circulating tumor DNA has the potential to be a minimally invasive, low cost, and reproducible method for cancer detection. We evaluated serum from 100 patients with known head and neck squamous cell carcinoma (HNSCC) and 50 healthy control patients for 3 previously described methylation targets, endothelin receptor type B (EDNRB), cyclin-dependent kinase inhibitor 2A (CDKN2A or p16), and deleted in colorectal carcinoma (DCC), using quantitative methylation specific polymerase chain reaction (qMSPCR). EDNRB hypermethylation was identified in the serum of 10% of the patients with HNSCC but in none of the control patients. DCC hypermethylation was detected in 2 serum samples from patients with cancer that also amplified EDNRB and one of these samples also had p16 hypermethylation. EDNRB hypermethylation was statistically significant by Fisher's exact test (p = .03) when comparing HNSCC to controls. Serum EDNRB hypermethylation is a highly specific but not sensitive serum biomarker for HNSCC.
Medical subject headings
- Biomarkers, Tumor
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Receptor, Endothelin B